Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Oslo, 20 December 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced today that cemiplimab (Libtayo) will be...
-
First clinical trial based on Ultimovacs’ proprietary TET adjuvant platform technologyFirst clinical trial based on Ultimovacs’ proprietary TET adjuvant platform technology12 patients with prostate...
-
Oslo, 29 November 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,500 shares in the company at an average price of...
-
Oslo, 21 November 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 16 November 2022 regarding the issuance of new shares in connection with the Company's employee incentive...
-
Oslo, 16 November 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital, related to the exercise of options, by NOK 13,070 through the...
-
Oslo, 10 November 2022, Radforsk Investeringstiftelse, a closely associated party of Jónas Einarsson, a primary insider and chair of the board of the Company, has today bought 5,250 shares in the...
-
Oslo, November 10, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its third quarter 2022 results today. Third Quarter...
-
Oslo, 3 November 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its third quarter 2022 results...
-
Fifth phase II trial assessing the impact of UV1 in various immunotherapy combinationsEnrollment of 138 patients at approximately all lung cancer centers in NorwayNon-small cell lung cancer is one of...
-
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Biomarker data support strong clinical responses from UV1 in combination...